(A) Immunoblot analysis of MOLT4 parental or CRBN−/− cells treated with ZNL-02-096 for 5 hrs; (B) Immunoblot analysis of MOLT4 cells pre-treated with DMSO, Carfilzomib (Carf.), MLN4924 (MLN), pomalidomide (Pom.), or AZD1775 for 2 hrs, and then co-treated with ZNL-02-096 for 5 hrs; (C) Immunoblot analysis of MOLT4 cells treated with ZNL-02-096 for the indicated time points; (D) Immunoblot analysis of MOLT4 cells treated with ZNL-02-096 or ZNL-02-178 for the indicated time points; (E) Log2 fold-change in abundance of proteins as measured using multiplexed quantitative-mass spectrometry-based proteomics of MOLT4 cells treated with ZNL-02-096 (100 nM) for 2 hrs vs. p-value. n = 3 biological replicates.